The efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia

Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an analysis of the PERSIST-2 trial (NCT02055781) focusing on the efficacy of pacritinib in patients with myelofibrosis (MF) with both anemia and thrombocytopenia. The analysis shows that pacritinib maintains efficacy in this subgroup, providing benefits in spleen size, symptom management, and anemia. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.